| Name | Nanatinostat |
| Description | Nanatinostat (CHR-3996) is an HDAC inhibitor with selectivity and oral bioavailability, with IC50 values of 3-7 nM for HDAC1/2/3 and >200 nM for other subtypes. Nanatinostat also inhibits tumour cell proliferation and induces apoptosis, for studying neurodegenerative diseases and cancer. |
| In vitro | Methods: Nanatinostat (CHR-3996) (30 mg/kg, oral) was used to treat NOD/SCID mice that were inoculated subcutaneously with 2×10^6 H929 myeloma cells on the right flank. Caliper measurements of the longest vertical tumor diameter (length) and width were performed every other day. Results: Nanatinostat slowed tumor growth in tumor-bearing mice. [2] |
| In vivo | Methods: H929, KMS11, LP-1, MM1-S, and RPMI-8828 cells were treated with Nanatinostat (CHR-3996) (0.0001-100 μM), and cell proliferation was detected by WST-1.
Results: The LC50 values of various cell lines treated with Nanatinostat ranged from 30.3-97.6 nM. [1] |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 40 mg/mL (101.42 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.07 mM), Sonication is recommended.
|
| Keywords | Nanatinostat | HDAC | CHR 3996 |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Manganese chloride (tetrahydrate) | Formamide | Dimethyl phthalate | Alginic acid | Sildenafil citrate |
| Related Compound Libraries | DNA Damage & Repair Compound Library | Histone Modification Compound Library | Bioactive Compound Library | Epigenetics Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Anti-Cancer Drug Library |
United States
